Home » Stocks » aTyr Pharma

aTyr Pharma, Inc. (LIFE)

Stock Price: $4.05 USD 0.05 (1.25%)
Updated Aug 10, 2020 2:14 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 37.91M
Revenue (ttm) 8.49M
Net Income (ttm) -15.71M
Shares Out 9.36M
EPS (ttm) -3.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $4.05
Previous Close $4.00
Change ($) 0.05
Change (%) 1.25%
Day's Open 4.07
Day's Range 3.95 - 4.10
Day's Volume 42,150
52-Week Range 2.13 - 7.62

More Stats

Market Cap 37.91M
Enterprise Value n/a
Earnings Date (est) Aug 13, 2020
Ex-Dividend Date n/a
Shares Outstanding 9.36M
Float 7.02M
EPS (basic) -4.5
EPS (diluted) -3.52
FCF / Share -1.76
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 43,546
Short Ratio 0.27
Short % of Float 0.36%
Beta 2.25
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.47
PB Ratio 0.89
Revenue 8.49M
Operating Income -15.24M
Net Income -15.71M
Free Cash Flow -12.11M
Net Cash 40.15M
Net Cash / Share 4.29
Gross Margin -160.55%
Operating Margin -179.59%
Profit Margin -185.10%
FCF Margin -142.72%
ROA -18.26%
ROE -44.43%
ROIC -58.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$11.50*
(183.95% upside)
Low
8.00
Current: $4.05
High
15.00
Target: 11.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue0.42------
Gross Profit0.42------
Operating Income-22.98-32.82-47.15-57.94-47.62-23.55-19.54
Net Income-23.60-34.52-48.21-57.86-47.97-24.35-20.01
Shares Outstanding3.362.141.851.691.130.060.05
Earnings Per Share-7.03-16.11-26.13-34.16-42.42-415.65-397.45
Operating Cash Flow-20.01-31.06-42.36-52.86-36.80-22.82-17.31
Capital Expenditures-0.03-0.59-1.31-0.60-0.66-0.25-0.64
Free Cash Flow-20.04-31.66-43.68-53.46-37.46-23.07-17.96
Cash & Equivalents31.1449.5585.1272.1595.5415.8536.46
Total Debt11.7316.0319.739.545.1410.286.89
Net Cash / Debt19.4133.5265.3962.6190.395.5829.57
Assets36.1952.7589.3680.5213020.6439.79
Liabilities15.1619.1025.1117.7214.63112106
Book Value21.1933.6564.2562.80115-91.01-68.50
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name aTyr Pharma, Inc.
Country United States
Employees 39
CEO Sanjay S. Shukla

Stock Information

Ticker Symbol LIFE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LIFE
IPO Date May 7, 2015

Description

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial. The company has a collaboration with the University of Nebraska Medical Center for the development of NRP2 biology; research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases; and research collaboration with Boston Children's Hospital. It also has license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was founded in 2005 and is headquartered in San Diego, California.